Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 473,800 shares, an increase of 136.2% from the September 30th total of 200,600 shares. Currently, 14.5% of the shares of the company are sold short. Based on an average daily volume of 368,100 shares, the short-interest ratio is presently 1.3 days.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “buy” rating and set a $7.00 price objective on shares of Biofrontera in a report on Friday, August 16th.

Biofrontera Trading Down 6.4 %

Shares of BFRI traded down $0.06 during mid-day trading on Friday, reaching $0.91. 43,484 shares of the stock traded hands, compared to its average volume of 378,697. Biofrontera has a 1 year low of $0.61 and a 1 year high of $5.28. The company has a market cap of $4.62 million, a price-to-earnings ratio of -0.07 and a beta of 0.50. The firm has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.18.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.19) by $0.07. The firm had revenue of $7.84 million for the quarter, compared to analysts’ expectations of $9.02 million. Biofrontera had a negative return on equity of 837.97% and a negative net margin of 38.34%. On average, sell-side analysts anticipate that Biofrontera will post -3.11 EPS for the current year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.